Correlation Between Mineralys Therapeutics, and First Wave

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and First Wave at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and First Wave into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and First Wave BioPharma, you can compare the effects of market volatilities on Mineralys Therapeutics, and First Wave and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of First Wave. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and First Wave.

Diversification Opportunities for Mineralys Therapeutics, and First Wave

0.43

Correlation Coefficient

Mineralys Therapeutics,  First Wave

Very weak diversification

The 3 months correlation between Mineralys and First is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and First Wave BioPharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on First Wave BioPharma and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with First Wave. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of First Wave BioPharma has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and First Wave go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and First Wave

If you would invest  1,211  in Mineralys Therapeutics, Common on September 29, 2024 and sell it today you would earn a total of  71.00  from holding Mineralys Therapeutics, Common or generate 5.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	1.59%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  First Wave BioPharma

Mineralys Therapeutics,

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

First Wave BioPharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days First Wave BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental drivers, First Wave is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders.

Pair Trading with Mineralys Therapeutics, and First Wave

The main advantage of trading using opposite Mineralys Therapeutics, and First Wave positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, First Wave can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in First Wave will offset losses from the drop in First Wave's long position.

The idea behind Mineralys Therapeutics, Common and First Wave BioPharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.